Relationship Between HIV-1 Subtype and ARV Response (RELATES)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00585793 |
Recruitment Status
:
Completed
First Posted
: January 3, 2008
Last Update Posted
: October 1, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HIV Infections | Drug: NRTI/NNRTI/ Kaletra |

Study Type : | Observational |
Actual Enrollment : | 108 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Study of the Relationship Between HIV-1 Subtype and Antiretroviral (ARV) Response in Ugandan Children |
Study Start Date : | July 2008 |
Actual Primary Completion Date : | February 2010 |
Actual Study Completion Date : | February 2010 |

Group/Cohort | Intervention/treatment |
---|---|
PEPFAR 1 |
Drug: NRTI/NNRTI/ Kaletra
Fixed dose and cild formulation Kaletra
|
- HIV-1 subtype affects response to ARVs [ Time Frame: 3 years ]
- Comparison of NNRTI/NRTI combinations to Kaletra/NRTI combinations in Ugandan Children [ Time Frame: 3 years ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Months to 16 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- PEPFAR eligible
Exclusion Criteria:
- OI/sfaety lab abnomalities

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00585793
Uganda | |
Kampala, Uganda |
Principal Investigator: | Frank M Graziano, MD/PhD | UWHC |
Responsible Party: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT00585793 History of Changes |
Other Study ID Numbers: |
H-2006-0206 |
First Posted: | January 3, 2008 Key Record Dates |
Last Update Posted: | October 1, 2015 |
Last Verified: | September 2015 |
Keywords provided by University of Wisconsin, Madison:
HIV/AIDS |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Lopinavir |
HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |